2025

2025114

PR Notice Regarding Completion of 30-Day Review for Clinical Trial Notification for Phase I/II Study of Cardiac Remuscularization Therapy HS-005 (Catheter Administration) Targeting Severe Heart Failure

2025911

PR Notice Regarding the New Partner for Delivery Catheter System for Allogeneic iPS Cell-Derived Cardiomyocyte Spheroids

2025421

Congress Takehiko Kaneko, CMO of Heartseed, to Speak at ISCT 2025 Annual Meeting

2025414

Congress Keiichi Fukuda, CEO, to Speak at the 25th World Congress of the International Society for Heart Research (ISHR)

2025313

Other Heartseed has started CEO column, "TOP MESSAGE", on Investor Relation section of its website.

202523

PR Heartseed Announces Enrollment Completion in Phase 1/2 Clinical Trial using HS-001, an Investigational Stem Cell-Derived Therapy for Advanced Heart Failure

1